Recognizing the potential of semaglutide for weight management, researchers developed Wegovy, a higher-dose version of semaglutide approved in 2021 explicitly for chronic weight management in patients with obesity or overweight with at least one weight-related comorbidity
The insurer said in a statement to Fierce Healthcare that it will no longer cover GLP-1s in its large group fully insured plans as of Jan
Among the plethora of novel agents against diabetes, GLP-1RAs are known to exert various biological effects in extra-pancreatic tissues beyond controlling hyperglycemia ( via central mechanisms ( Similarly, SGLT-2is, also referred to as gliflozins, represent another class of anti-hyperglycemic agents currently used in T2D treatment with favorable effects on body weight
Affordable and Convenient Options Oana Health also prioritizes affordability
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer
Teriparatide and abaloparatide exploit the bone-forming effects of intermittent PTH exposure to stimulate osteoblast activity and increase bone mass
